Results 21 to 30 of about 445,623 (380)
Cell Proliferation, 2021 High‐mobility group box‐1 (HMGB1) and aberrant mitochondrial fission mediated by excessive activation of GTPase dynamin‐related protein 1 (Drp1) have been found to be elevated in patients with pulmonary arterial hypertension (PAH) and critically ...
Wei Feng +12 more
semanticscholar +1 more source
A multiscale model of vascular function in chronic thromboembolic pulmonary hypertension [PDF]
, 2021 Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by recurrent or unresolved pulmonary thromboemboli, leading to perfusion defects and increased arterial wave reflections. CTEPH treatment aims to reduce pulmonary arterial pressure and reestablish adequate lung perfusion, yet patients with distal lesions are inoperable by standard surgical
arxiv +1 more source
Altered Gut Microbiome Profile in Patients With Pulmonary Arterial Hypertension
HYPERTENSION, 2020 Supplemental Digital Content is available in the text. Pulmonary arterial hypertension (PAH) is considered a disease of the pulmonary vasculature. Limited progress has been made in preventing or arresting progression of PAH despite extensive efforts. Our
Seungbum Kim +6 more
semanticscholar +1 more source
BMC Pulmonary Medicine, 2017 Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum +9 more
doaj +1 more source
Pulmonary Circulation, 2021 Pulmonary arterial hypertension is a heterogeneous group of diseases characterized by vascular cell proliferation leading to pulmonary vascular remodelling and ultimately right heart failure. Previous data indicated that 3′‐deoxy‐3′‐[18F]‐fluorothymidine
Liza Botros +11 more
doaj +1 more source
Effect of riociguat on pulmonary arterial compliance in the PATENT and CHEST studies
Pulmonary Circulation, 2020 Pulmonary arterial compliance is a measure of the pulsatile afterload of the right ventricle. Lower pulmonary arterial compliance is associated with reduced right ventricular function and worse prognosis in pulmonary hypertension. The effect of pulmonary
Thenappan Thenappan +9 more
doaj +1 more source
Pulmonary Circulation, 2020 Platelet-derived growth factor is one of the major growth factors found in human and mammalian serum and tissues. Abnormal activation of platelet-derived growth factor signaling pathway through platelet-derived growth factor receptors may contribute to ...
Kang Wu +21 more
doaj +1 more source
Parameter inference in a computational model of hemodynamics in pulmonary hypertension [PDF]
, 2021 Pulmonary hypertension (PH), defined by a mean pulmonary arterial pressure (mPAP) $>$ 20 mmHg, is characterized by increased pulmonary vascular resistance and decreased pulmonary arterial compliance. There are few measurable biomarkers of PH progression, but a conclusive diagnosis of the disease requires invasive right heart catheterization (RHC ...
arxiv +1 more source
Multiscale modelling of reversed Potts shunt as a potential palliative treatment for suprasystemic idiopathic pulmonary artery hypertension in children [PDF]
Biomechanics and Modeling in Mechanobiology (2022), 2021 Reversed Potts shunt (PS) was suggested as palliation for patients with suprasystemic pulmonary arterial hypertension (PAH) and right ventricular (RV) failure. PS, however, can result in poorly understood mortality. Here, a patient-specific geometrical multiscale model of PAH physiology and PS is developed for a paediatric PAH patient with stent-based ...
arxiv +1 more source
Risk stratification and medical therapy of pulmonary arterial hypertension
European Respiratory Journal, 2019 Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways.
N. Galiè +10 more
semanticscholar +1 more source